Her2-positive breast cancer: Herceptin and beyond

European Journal of Cancer

Volumn 44, Issue 18, 2008, Pages 2806-2812

  Dean Colomb, Windy ^a   Esteva, Francisco J ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Breast cancer; Her2; mTOR inhibitors; Trastuzumab; Tyrosine kinase inhibitors

Indexed keywords

AUY 922; BORTEZOMIB; CAPECITABINE; CNF 2024; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPOTHILONE D; ERTUMAXOMAB; EVEROLIMUS; GEFITINIB; HEAT SHOCK PROTEIN 90 INHIBITOR; HISTONE DEACETYLASE INHIBITOR; IRINOTECAN; IXABEPILONE; LAPATINIB; LAROTAXEL; LONAFARNIB; PACLITAXEL; PANOBINOSTAT; PERTUZUMAB; RAPAMYCIN; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; SUNITINIB; TAK 165; TANESPIMYCIN; TEMSIROLIMUS; TIPIFARNIB; TRASTUZUMAB; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; BREAST METASTASIS; CANCER EPIDEMIOLOGY; CANCER PREVENTION; CANCER SURVIVAL; CANCER THERAPY; CLINICAL TRIAL; DRUG EFFICACY; DRUG INHIBITION; DRUG MECHANISM; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SINGLE DRUG DOSE; TREATMENT DURATION;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DRUG RESISTANCE, NEOPLASM; FEMALE; GENES, ERBB-2; HUMANS; RECEPTOR, ERBB-2; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 56949108012     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2008.09.013     Document Type: Article

References (66)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2006. CA Cancer J Clin 56 2 (2006) 106-130
2. Slamon D.J. Proto-oncogenes and human cancers. N Engl J Med 317 15 (1987) 955-957
3. Esteva F.J., Cheli C.D., Fritsche H., et al. Clinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies. Breast Cancer Res 7 4 (2005) R436-R443
4. Mazouni C., Hall A., Broglio K., et al. Kinetics of serum HER-2/neu changes in patients with HER-2-positive primary breast cancer after initiation of primary chemotherapy. Cancer 109 3 (2007) 496-501
5. Graus-Porta D., Beerli R.R., Daly J.M., and Hynes N.E. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J 16 7 (1997) 1647-1655
6. Sliwkowski M.X., Lofgren J.A., Lewis G.D., et al. Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). Semin Oncol 26 4 Suppl. 12 (1999) 60-70
7. Baselga J., Albanell J., Molina M.A., and Arribas J. Mechanism of action of trastuzumab and scientific update. Semin Oncol 28 5 Suppl. 16 (2001) 4-11
8. Schlessinger J. Common and distinct elements in cellular signaling via EGF and FGF receptors. Science 306 5701 (2004) 1506-1507
9. Petit A.M., Rak J., Hung M.C., et al. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. Am J Pathol 151 6 (1997) 1523-1530
10. Janes P.W., Daly R.J., deFazio A., and Sutherland R.L. Activation of the Ras signalling pathway in human breast cancer cells overexpressing erbB-2. Oncogene 9 12 (1994) 3601-3608
11. Ferretti G., Felici A., Papaldo P., Fabi A., and Cognetti F. HER2/neu role in breast cancer: from a prognostic foe to a predictive friend. Curr Opin Obstet Gynecol 19 1 (2007) 56-62
12. Izumi Y., Xu L., di Tomaso E., Fukumura D., and Jain R.K. Tumour biology: herceptin acts as an anti-angiogenic cocktail. Nature 416 6878 (2002) 279-280
13. Wen X.F., Yang G., Mao W., et al. HER2 signaling modulates the equilibrium between pro- and antiangiogenic factors via distinct pathways: implications for HER2-targeted antibody therapy. Oncogene 25 52 (2006) 6986-6996
14. Nieto Y., Woods J., Nawaz F., et al. Prognostic analysis of tumour angiogenesis, determined by microvessel density and expression of vascular endothelial growth factor, in high-risk primary breast cancer patients treated with high-dose chemotherapy. Br J Cancer 97 3 (2007) 391-397
15. Vamesu S. Angiogenesis and c-erbB-2 (HER2/neu) overexpression status in primary breast cancer patients: an analysis of 158 needle core biopsies. Rom J Morphol Embryol 48 2 (2007) 121-129
16. Wolff A.C., Hammond M.E., Schwartz J.N., et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25 1 (2007) 118-145
17. Nahta R., and Esteva F.J. Trastuzumab: triumphs and tribulations. Oncogene 26 25 (2007) 3637-3643
18. Baselga J., Tripathy D., Mendelsohn J., et al. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 14 3 (1996) 737-744
19. Cobleigh M.A., Vogel C.L., Tripathy D., et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17 9 (1999) 2639-2648
20. Vogel C.L., Cobleigh M.A., Tripathy D., et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20 3 (2002) 719-726
21. Baselga J., Carbonell X., Castaneda-Soto N.J., et al. Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule. J Clin Oncol 23 10 (2005) 2162-2171
22. Slamon D.J., Leyland-Jones B., Shak S., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344 11 (2001) 783-792
23. Esteva F.J., Valero V., Booser D., et al. Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 20 7 (2002) 1800-1808
24. Burstein H.J., Harris L.N., Marcom P.K., et al. Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm. J Clin Oncol 21 15 (2003) 2889-2895
25. Pegram M.D., Pienkowski T., Northfelt D.W., et al. Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer. J Natl Cancer Inst 96 10 (2004) 759-769
26. Bartsch R., Wenzel C., Altorjai G., et al. Capecitabine and trastuzumab in heavily pretreated metastatic breast cancer. J Clin Oncol 25 25 (2007) 3853-3858
27. O'Shaughnessy J.A., Vukelja S., and Marsland T. Phase II study of trastuzumab plus gemcitabine in chemotherapy-pretreated patients with metastatic breast cancer. Clin Breast Cancer 5 2 (2004) 142-147
28. Mackey J.R., Kaufman B., Clemens M., et al. Trastuzumab prolongs progression-free survival in hormone-dependent and HER2-positive metastatic breast cancer. Breast Cancer Res Treat 100 Suppl. 1 (2006) Abstract #3
29. Marcom P.K., Isaacs C., Harris L., et al. The combination of letrozole and trastuzumab as first or second-line biological therapy produces durable responses in a subset of HER2 positive and ER positive advanced breast cancers. Breast Cancer Res Treat 102 1 (2007) 43-49
30. Gonzalez-Angulo A.M., Hortobagyi G.N., and Esteva F.J. Adjuvant therapy with trastuzumab for HER-2/neu-positive breast cancer. Oncologist 11 8 (2006) 857-867
31. Piccart-Gebhart M.J., Procter M., Leyland-Jones B., et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353 16 (2005) 1659-1672
32. Romond E.H., Perez E.A., Bryant J., et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353 16 (2005) 1673-1684
33. Buzdar A.U., Valero V., Ibrahim N.K., et al. Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen. Clin Cancer Res 13 1 (2007) 228-233
34. Esteva F.J., Wang J., Lin F., et al. CD40 signaling predicts response to preoperative trastuzumab and concomitant paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide in HER-2-overexpressing breast cancer. Breast Cancer Res 9 6 (2007) R87
35. Telli M.L., Hunt S.A., Carlson R.W., and Guardino A.E. Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility. J Clin Oncol 25 23 (2007) 3525-3533
36. Guarneri V., Lenihan D.J., Valero V., et al. Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience. J Clin Oncol 24 25 (2006) 4107-4115
37. Nahta R., Yu D., Hung M.C., Hortobagyi G.N., and Esteva F.J. Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nat Clin Pract Oncol 3 5 (2006) 269-280
38. Nahta R., and Esteva F.J. HER2 therapy: molecular mechanisms of trastuzumab resistance. Breast Cancer Res 8 6 (2006) 215
39. Nahta R., Yuan L.X., Zhang B., Kobayashi R., and Esteva F.J. Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer Res 65 23 (2005) 11118-11128
40. Nagata Y., Lan K.H., Zhou X., et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 6 2 (2004) 117-127
41. Lu C.H., Wyszomierski S.L., Tseng L.M., et al. Preclinical testing of clinically applicable strategies for overcoming trastuzumab resistance caused by PTEN deficiency. Clin Cancer Res 13 19 (2007) 5883-5888
42. Nahta R., Takahashi T., Ueno N.T., Hung M.C., and Esteva F.J. P27(kip1) down-regulation is associated with trastuzumab resistance in breast cancer cells. Cancer Res 64 11 (2004) 3981-3986
43. Scaltriti M., Rojo F., Ocana A., et al. Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. J Natl Cancer Inst 99 8 (2007) 628-638
44. Agus D.B., Akita R.W., Fox W.D., et al. Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell 2 2 (2002) 127-137
45. Nahta R., Hung M.C., and Esteva F.J. The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells. Cancer Res 64 7 (2004) 2343-2346
46. Friess T., Scheuer W., and Hasmann M. Combination treatment with erlotinib and pertuzumab against human tumor xenografts is superior to monotherapy. Clin Cancer Res 11 14 (2005) 5300-5309
47. Gordon M.S., Matei D., Aghajanian C., et al. Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status. J Clin Oncol 24 26 (2006) 4324-4332
48. Agus D.B., Sweeney C.J., Morris M.J., et al. Efficacy and safety of single-agent pertuzumab (rhuMAb 2C4), a human epidermal growth factor receptor dimerization inhibitor, in castration-resistant prostate cancer after progression from taxane-based therapy. J Clin Oncol 25 6 (2007) 675-681
49. Persson M., Gedda L., Lundqvist H., et al. [177Lu]pertuzumab: experimental therapy of HER-2-expressing xenografts. Cancer Res 67 1 (2007) 326-331
50. Nahta R., Yuan L.X., Du Y., and Esteva F.J. Lapatinib induces apoptosis in trastuzumab-resistant breast cancer cells: effects on insulin-like growth factor I signaling. Mol Cancer Ther 6 2 (2007) 667-674
51. Geyer C.E., Forster J., Lindquist D., et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355 26 (2006) 2733-2743
52. Asnaghi L., Bruno P., Priulla M., and Nicolin A. MTOR: a protein kinase switching between life and death. Pharmacol Res 50 6 (2004) 545-549
53. Janus A., Robak T., and Smolewski P. The mammalian target of the rapamycin (mTOR) kinase pathway: its role in tumourigenesis and targeted antitumour therapy. Cell Mol Biol Lett 10 3 (2005) 479-498
54. Zhou X., Tan M., Stone Hawthorne V., et al. Activation of the Akt/mammalian target of rapamycin/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers. Clin Cancer Res 10 20 (2004) 6779-6788
55. Yu K., Toral-Barza L., Discafani C., et al. MTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer. Endocr Relat Cancer 8 3 (2001) 249-258
56. Noh W.C., Mondesire W.H., Peng J., et al. Determinants of rapamycin sensitivity in breast cancer cells. Clin Cancer Res 10 3 (2004) 1013-1023
57. Mosley J.D., Poirier J.T., Seachrist D.D., Landis M.D., and Keri R.A. Rapamycin inhibits multiple stages of c-Neu/ErbB2 induced tumor progression in a transgenic mouse model of HER2-positive breast cancer. Mol Cancer Ther 6 8 (2007) 2188-2197
58. King C.R., Kasprzyk P.G., Fischer P.H., Bird R.E., and Turner N.A. Preclinical testing of an anti-erbB-2 recombinant toxin. Breast Cancer Res Treat 38 1 (1996) 19-25
59. Engebraaten O., Sivam G., Juell S., and Fodstad O. Systemic immunotoxin treatment inhibits formation of human breast cancer metastasis and tumor growth in nude rats. Int J Cancer 88 6 (2000) 970-976
60. Azemar M., Djahansouzi S., Jager E., et al. Regression of cutaneous tumor lesions in patients intratumorally injected with a recombinant single-chain antibody-toxin targeted to ErbB2/HER2. Breast Cancer Res Treat 82 3 (2003) 155-164
61. von Minckwitz G., Harder S., Hovelmann S., et al. Phase I clinical study of the recombinant antibody toxin scFv(FRP5)-ETA specific for the ErbB2/HER2 receptor in patients with advanced solid malignomas. Breast Cancer Res 7 5 (2005) R617-R626
62. Weiner L.M., O'Dwyer J., Kitson J., et al. Phase I evaluation of an anti-breast carcinoma monoclonal antibody 260F9-recombinant ricin A chain immunoconjugate. Cancer Res 49 14 (1989) 4062-4067
63. Pai-Scherf L.H., Villa J., Pearson D., et al. Hepatotoxicity in cancer patients receiving erb-38, a recombinant immunotoxin that targets the erbB2 receptor. Clin Cancer Res 5 9 (1999) 2311-2315
64. Slamon D, Eiermann W, Robert N, et al. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC TH) with docetaxxel, carboplatin and trastuzumab (TCH) in HER2 positive early breast cancer patients: BCIRG 006 study. In: Presented at the 28th annual San Antonio breast cancer symposium, December 8-11, 2005, San Antonio, TX, USA.
65. Joensuu H., Kellokumpu-Lehtinen P.L., Bono P., et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 354 (2006) 809-820
66. http://www.clinicaltrials.gov; [Accessed 28.12.2007].